Catalyst
Slingshot members are tracking this event:
Neurocrine Announces Initiation of Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Children and Adolescents with Tourette Syndrome
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
NBIX | Community voting in process |
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 02, 2016
Related Projects
Related Keywords
Phase Ii Clinical Study, Vmat2 Inhibitor, Valbenazine, Tourette Syndrome